Amylyx Pharmaceuticals is a clinical-stage pharmaceutical company developing novel therapies for endocrine and neurodegenerative diseases with significant unmet medical needs. Its lead asset, avexitide, is a first-in-class GLP-1 receptor antagonist designed to treat hyperinsulinemic hypoglycemia conditions including post-bariatric hypoglycemia and congenital hyperinsulinism, supported by regulatory designations including Breakthrough Therapy and Orphan Drug status. The company also pursues secondary programs targeting Wolfram syndrome, amyotrophic lateral sclerosis, and additional rare metabolic disorders through various drug modalities, generating revenue potential through FDA approvals and commercialization of therapies for orphan indications where few treatment options exist.